Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
CytoDyn Inc CYDY
(Total Views: 997)
Posted On: 11/22/2020 3:59:01 AM
Post# of 155026
Posted By: 123kidc
Re: 123kidc #66166
Further important quote from the corresponding FDA letter (meaning that this EUA poses no hindering for a possible Leronlimab approval):

"Casirivimab and imdevimab is not authorized for use in the following patient
populations (5):
• Adults or pediatric patients who are hospitalized due to COVID-19, or
• Adults or pediatric patients who require oxygen therapy due to COVID-
19, or
• Adults or pediatric patients who require an increase in baseline oxygen
flow rate due to COVID-19 in those patients on chronic oxygen therapy
due to underlying non-COVID-19-related comorbidity.

(5): Benefit of treatment with casirivimab and imdevimab has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies, such as casirivimab and imdevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation."

https://www.fda.gov/media/143891/download













(2)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site